We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Stock Type |
|---|---|---|---|
| Amryt Pharma Plc | AMYT | London | Ordinary Share |
| Price Change | Price Change % | Share Price | Last Trade
|
|
|---|---|---|---|---|
| 0.00 | 0.00% | 143.00 | 01:00:00 |
| Open Price | Low Price | High Price | Close Price | Previous Close |
|---|---|---|---|---|
| 143.00 |
| Top Posts |
|---|
Posted at 10/1/2023 08:57 by punter6 Sold out yesterday for $14.50 per ADR and now officially out of AMYT.The CGT computation is going to be some headache! Best of luck to the rest of you! |
Posted at 17/10/2022 14:20 by punter6 Broker got my funds from AMYT last week. |
Posted at 22/4/2022 15:44 by chica1 Sorry I missed that CVR's will be paidCHMP adopts positive opinion for Filsuvez® for the treatment of Dystrophic and Junctional EB Positive opinion based on largest ever pivotal global Phase 3 EASE study undertaken in EB Filsuvez® would be the first and only approved treatment in Europe for EB Patients DUBLIN, Ireland, and Boston MA, April 22, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval of Filsuvez® in the European Union (EU) for the treatment of partial thickness wounds associated with dystrophic and junctional Epidermolysis Bullosa (EB) in patients 6 months and older. EB is a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment. Based on this CHMP recommendation a decision by the European Commission (EC) is expected on the Filsuvez® application within 67 days. The centralised marketing authorisation would be valid in all EU Member States as well as in Iceland, Liechtenstein, and Norway. The Medicines and Healthcare products Regulatory Agency (MHRA) in the UK is expected to grant authorisation within the same time period. The CHMP positive opinion is supported by Phase 3 data from the EASE trial which was the largest ever global trial conducted in patients with EB, performed across 58 sites in 28 countries. As a result of the CHMP positive opinion, the EMA Contingent Value Right (CVR) issued to Amryt shareholders and option holders prior to the acquisition of Aegerion will now become payable. The quantum of the EMA CVR payable will be determined by the terms of the CVR Deed Poll and CVR holders will be notified in due course of their entitlement |
Posted at 22/4/2022 15:36 by chica1 Interesting the news today but wasn't Episalvan approved for partial thickness wounds by the EMA in 2015DUBLIN, Ireland, and Boston MA, April 22, 2022, Amryt (Nasdaq: AMYT), a global, commercial-stage biopharmaceutical company focussed on acquiring, developing and commercializing novel treatments for rare diseases, is pleased to announce that the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) has adopted a positive opinion, recommending the approval of Filsuvez® in the European Union (EU) for the treatment of partial thickness wounds associated with dystrophic and junctional Epidermolysis Bullosa (EB) in patients 6 months and older. EB is a rare and distressing genetic skin disorder affecting young children and adults for which there is currently no approved treatment. |
Posted at 27/3/2022 20:08 by alphabravo321 https://tickeron.com |
Posted at 01/3/2022 11:50 by papillon Nasdaq investors got it correct around 9 months ago. AMYT obviously overpaid for their latest acquisition. That acquisition was a sign of desperation on the part of Wiley, but UK investors, including me, were slow to acknowledge that fact. An acquisition was the only way AMYT were going to get another drug to add to their existing 2 (and Wiley guessed it) and they had to overpay to acquire it. |
Posted at 28/2/2022 15:22 by papillon AMYT being Hammered on Nasdaq. Currently down 20% @ $6.50Glad I sold before Christmas after the RNS saying it was to delist from AIM. The AMYT chart has been dreadful for a long time. It pays to follow the charts. I had mentally written off the CVR's as junk. My doubts were confirmed today. |
Posted at 10/1/2022 21:41 by papillon I wish you all the very best with AMYT in the USA, richpassi. I have never held a share on an exchange outside of the UK and I'm a bit too long in the tooth to start now. That's the reason I sold my AMYT shares as I believe the future looks bright for holders. Let's hope they multi bag for you! |
Posted at 23/11/2021 17:08 by brummy_git A very busy couple of days for Amryt PharmaFind out here my latest views & 'back of the envelope' valuation. www.linkedin.com/pos |
Posted at 29/7/2021 01:51 by papillon Actually Adw198 both the LSE & Nasdaq AMYT charts went bearish in May when the falling 50 day EMA went below the already falling 200 day EMA. A so called "Death Cross". I'd already sold all my AMYT shares before that happened. I sold on the day (5th May?) when AMYT announced that takeover. I sold because I looked at the pre market quote for AMYT on Nasdaq and it had dropped like a stone, so I didn't sell because of any charts!!I bought back into AMYT in June because the AMYT Ichimoku chart turned weakly bullish (not strongly bullish). Why? Because I believe in AMYT having held them for years, since FAST relisted as AMYT in May 2016, through thick and thin. You could say my heart overruled my head However that Ichimoku chart soon turned strongly bearish again and I sold all the AMYT shares, I had only recently bought, at a loss and invested the proceeds elsewhere. With the benefit of hindsight it was the correct thing to do. This time my head overruled my heart. Unfortunately the 200 day EMA is still falling as is the 50 day EMA, which has stayed below the 200 day EMA ever since that Bearish Death Cross appeared on the chart. Why did the Nasdaq investors react so badly to that takeover, when the AIM investors had initially pushed up the share price when the deal was announced at noon and before Nasdaq opened? I've no idea, Adw198. Unfortunately AMYT's primary listing is now on Nasdaq and not on AIM these days. AMYT is an Irish company and at least 70% of the AMYT shares are held as ADS's on Nasdaq. Yankee investors call the tune and they obviously didn't like the news of the acquisition. Did they think AMYT had overpaid? Probably. The company taken over is American so they probably know more about the company than we do. I'd like to buy AMYT shares again, but it will be because my head says so and not because of my heart. I've lost lots of money in the past falling in love with a share. I'm not about to do it again. What you do is up to you; you pays your money and you takes your choice. It's your money, just like it's my money. We can spend it how we see fit. At the moment I don't see why I should sell some of my other shares to buy AMYT shares. |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
